Apogee Therapeutics, Inc.APGE
Immunology10 cited findings · profile updated 2026-08-25
134.79 USDnot live — refreshed daily
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. (APGE) is focused on immunology. The company is developing zumilokibart, which is currently in Phase 2 development in the APEX Part B trial. In this trial, zumilokibart demonstrated an EASI-75 response rate of 65.9% and a placebo-adjusted EASI-75 response rate of 41.9%. Other efficacy measures for zumilokibart in the APEX Part B trial include an IGA 0/1 response rate of 46.0%, an EASI-90 response rate of 47.4%, and an I-NRS ≥4 improvement of 50.5%. The drug also showed an EASI-100 response rate of 16.5% and very low disease activity (vLDA) of 20.6% in the same trial. Zumilokibart is also being investigated in the Phase 2a ELEVATE trial and the Phase 2b ASPIRE trial.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| EASI-75 response rate | 65.9 % (zumilokibart (APEX Part B)) | Apogee Therapeutics, Inc. — SEC 8-K (2026-08-10), p.2 |
| EASI-75 response rate (placebo adjusted) | 41.9 % (zumilokibart (APEX Part B)) | Apogee Therapeutics, Inc. — SEC 8-K (2026-08-10), p.2 |
| IGA 0/1 response rate | 46.0 % (zumilokibart (APEX Part B)) | Apogee Therapeutics, Inc. — SEC 8-K (2026-08-10), p.2 |
| EASI-90 response rate | 47.4 % (zumilokibart (APEX Part B)) | Apogee Therapeutics, Inc. — SEC 8-K (2026-08-10), p.2 |
| I-NRS ≥4 improvement | 50.5 % (zumilokibart (APEX Part B)) | Apogee Therapeutics, Inc. — SEC 8-K (2026-08-10), p.2 |
| Very low disease activity (vLDA) | 20.6 % (zumilokibart (APEX Part B)) | Apogee Therapeutics, Inc. — SEC 8-K (2026-08-10), p.2 |
Key projects
- zumilokibart
zumilokibart is in Phase 2 development in the APEX Part B trial.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Immunology research library →